Last moves
Peptide Exchange
0molecules on your watchlist

Incretins

Retatrutide

Code LY3437943

Lilly's weekly triple incretin agonist, in phase 3 for obesity with a US filing planned for early 2027. A phase 2b kidney study left measured GFR unchanged at 24 weeks while albuminuria and glomerular pressure fell.

Retatrutide comes from Eli Lilly and sits in the Incretins class on the board. Route: weekly injection. Use tracked here: Obesity or overweight, also studied in type 2 diabetes and chronic kidney disease. It stands at Phase 3 on the board, with 6 news moves logged; the latest is dated 3 Nov 2026.

  1. 03Phase 3Here now
  2. 02Phase 2Does it work at all, and at which dose? Hundreds of patients.
  3. 01Phase 1First doses in people. Safety, dose range, how the body handles it.
Company
Eli Lilly
Mechanism
Triple agonist of the GIP, GLP-1 and glucagon receptors
Given as
weekly injection
Lead use on the board
Obesity or overweight, also studied in type 2 diabetes and chronic kidney disease
Moves logged
6latest today

Retatrutide news moves

  1. ■ ExplainerHolds P3

    Malaysia seizes 697 units of unapproved retatrutide as Lilly readies its FDA filing

    Malaysia's Health Ministry told Parliament it seized 697 units of unregistered retatrutide in 12 raids since 2025. Lilly's triple agonist is still in Phase 3, with a US filing planned for the first quarter of 2027, so no product can be legally sold.

  2. ■ ExplainerHolds P3

    Retatrutide weight loss plateau hopes outpace the Phase 3 evidence

    A UK GP says she will switch patients stuck on Mounjaro to Lilly's retatrutide once it is approved. The Phase 3 data show large losses against placebo, but no switch study, more side effects at the top dose, and a US filing not due until early 2027.

  3. ■ ExplainerHolds P3

    Retatrutide side effects rise with dose in the Ozempic head to head trial

    Lilly's triple agonist beat the top Ozempic dose on A1C and weight in TRANSCEND-T2D-2, but 7.9% on the higher dose stopped for adverse events versus 2.7% on Ozempic. The lower dose kept most of the benefit.

  4. ▲ ReadoutHolds P3

    Retatrutide vs Ozempic Phase 3 trial doubles weight loss in type 2 diabetes

    Lilly's weekly triple agonist lowered A1C more than the top Ozempic dose and roughly doubled its weight loss at 80 weeks in TRANSCEND-T2D-2. The data are topline and open label, and more people stopped the higher dose for side effects.

  5. ▲ ReadoutHolds P3

    Retatrutide sleep apnea benefit was larger without diabetes in the TRIUMPH OSA trials

    Two phase 3 TRIUMPH substudies in 691 adults, published in NEJM, show the Lilly triple agonist lowering the apnea hypopnea index well beyond placebo over 80 weeks. Gains were smaller in people with type 2 diabetes.

  6. ■ ReadoutHolds P3

    Retatrutide kidney trial lowers albuminuria while measured GFR holds flat

    In the phase 2b TRANSCEND-CKD study, measured filtration did not differ from placebo at 24 weeks, but albuminuria, glomerular pressure and kidney fat fell. Retatrutide stays in phase 3, and the earlier estimated GFR gains now look like a weight loss effect.